PT2970467T - Anticorpos anti-cd52 - Google Patents

Anticorpos anti-cd52

Info

Publication number: PT2970467T
Authority: PT; Portugal
Prior art keywords: antibodies
Prior art date: 2013-03-15

Application number

PT14714135T

Other languages

English (en)

Inventor

Qiu Huawei

Rong Wei Ronnie

Qun Pan Clark

Sendak Rebecca

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-13

Publication date

2019-01-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2970467(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-13 Application filed by Genzyme Corp filed Critical Genzyme Corp

2019-01-28 Publication of PT2970467T publication Critical patent/PT2970467T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT14714135T 2013-03-15 2014-03-13 Anticorpos anti-cd52 PT2970467T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361794576P	2013-03-15	2013-03-15

Publications (1)

Publication Number	Publication Date
PT2970467T true PT2970467T (pt)	2019-01-28

Family

ID=50391542

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT14714135T PT2970467T (pt)	2013-03-15	2014-03-13	Anticorpos anti-cd52

Country Status (36)

Country	Link
US (2)	US9708407B2 (pt)
EP (1)	EP2970467B1 (pt)
JP (2)	JP6482524B2 (pt)
KR (1)	KR20150131286A (pt)
CN (1)	CN105209495B (pt)
AR (1)	AR095199A1 (pt)
AU (1)	AU2014233685B2 (pt)
BR (1)	BR112015022464A2 (pt)
CA (1)	CA2906539A1 (pt)
CL (1)	CL2015002705A1 (pt)
CR (1)	CR20150547A (pt)
CY (1)	CY1121795T1 (pt)
DK (1)	DK2970467T3 (pt)
DO (1)	DOP2015000211A (pt)
EA (1)	EA031730B1 (pt)
ES (1)	ES2710976T3 (pt)
GT (1)	GT201500267A (pt)
HK (1)	HK1219963A1 (pt)
HR (1)	HRP20190085T1 (pt)
HU (1)	HUE041796T2 (pt)
IL (1)	IL241410A0 (pt)
LT (1)	LT2970467T (pt)
MA (1)	MA38485A1 (pt)
MX (1)	MX2015012991A (pt)
NZ (1)	NZ631473A (pt)
PE (1)	PE20151757A1 (pt)
PH (1)	PH12015501932A1 (pt)
PL (1)	PL2970467T3 (pt)
PT (1)	PT2970467T (pt)
SG (1)	SG11201506932SA (pt)
SI (1)	SI2970467T1 (pt)
TN (1)	TN2015000415A1 (pt)
TR (1)	TR201900638T4 (pt)
TW (1)	TWI644923B (pt)
UY (1)	UY35440A (pt)
WO (1)	WO2014151644A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI1013085A2 (pt)	2009-05-13	2020-11-03	Genzyme Corporation	imunoglobulinas anti-cd52 humana
CA2761885A1 (en)	2009-05-13	2010-11-18	Genzyme Corporation	Methods and compositions for treating lupus
PL3079322T3 (pl) *	2014-01-28	2021-01-11	Huawei Technologies Co., Ltd.	Sposób wskazywania transmisji danych, punkt dostępowy i terminal
CN110546167A (zh) *	2017-04-21	2019-12-06	建新公司	以抗-cd52抗体治疗多发性硬化症
BR112020015915A8 (pt) *	2018-02-13	2023-01-31	Merck Sharp & Dohme	Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
WO2021022044A1 (en) *	2019-07-31	2021-02-04	Forty Seven, Inc.	Depletion regimes for engineered t-cell or nk-cell therapy
WO2024038839A1 (ja) *	2022-08-15	2024-02-22	国立大学法人東京大学	糸状菌を用いた免疫グロブリンまたは多量体免疫グロブリンの製造方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4970198A (en)	1985-10-17	1990-11-13	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
WO1987006265A1 (en)	1986-04-17	1987-10-22	Kyowa Hakko Kogyo Co., Ltd.	Novel compounds dc-88a and dc-89a1 and process for their preparation
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
JP3095168B2 (ja)	1988-02-05	2000-10-03	エル．モリソン，シェリー	ドメイン‐変性不変部を有する抗体
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JP2598116B2 (ja)	1988-12-28	1997-04-09	協和醗酵工業株式会社	新規物質ｄｃ１１３
US5187186A (en)	1989-07-03	1993-02-16	Kyowa Hakko Kogyo Co., Ltd.	Pyrroloindole derivatives
JP2510335B2 (ja)	1989-07-03	1996-06-26	協和醗酵工業株式会社	Ｄｃ―８８ａ誘導体
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
GB9022547D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Purified immunoglobulin
GB9108056D0 (en)	1991-04-16	1991-06-05	Hale Geoffrey	Synthetic antigen
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5264586A (en)	1991-07-17	1993-11-23	The Scripps Research Institute	Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en)	1991-11-12	1993-12-14	Stress-Tek, Inc.	Weighing bed
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
WO1994026087A2 (en)	1993-05-14	1994-11-24	Connor Kim C O	Recombinant protein production and insect cell culture and process
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
US7119248B1 (en)	1994-04-12	2006-10-10	Miltenyi Biotec Gmbh	Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
DE69533277T2 (de)	1994-04-22	2005-07-21	Kyowa Hakko Kogyo Co., Ltd.	Dc-89 derivat
US5550246A (en)	1994-09-07	1996-08-27	The Scripps Research Institute	Calicheamicin mimics
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP0983303B1 (en)	1997-05-21	2006-03-08	Biovation Limited	Method for the production of non-immunogenic proteins
US6172213B1 (en)	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
CA2342967A1 (en)	1998-12-08	2000-06-15	Biovation Limited	Modifying protein immunogenicity
DK1242401T3 (da)	1999-11-24	2007-05-07	Immunogen Inc	Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
DE60136527D1 (de)	2000-03-03	2008-12-24	Cambridge Antibody Tech	Antikörper gegen eotaxin und deren verwendung
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en)	2000-10-09	2008-12-16	Isis Innovation, Inc.	Therapeutic antibodies
US20020132983A1 (en)	2000-11-30	2002-09-19	Junghans Richard P.	Antibodies as chimeric effector cell receptors against tumor antigens
WO2003048731A2 (en)	2001-12-03	2003-06-12	Abgenix, Inc.	Antibody categorization based on binding characteristics
EP3960855A1 (en)	2001-12-28	2022-03-02	Chugai Seiyaku Kabushiki Kaisha	Method for stabilizing proteins
WO2003074679A2 (en)	2002-03-01	2003-09-12	Xencor	Antibody optimization
US20050191632A1 (en)	2002-11-01	2005-09-01	John Byrd	Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh)	2002-12-18	2005-11-02	马菁	抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en)	2002-12-31	2009-05-19	Immunomedics, Inc.	Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR20060002896A (ko)	2003-03-31	2006-01-09	기린 비루 가부시키가이샤	항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
US7709224B2 (en)	2003-06-03	2010-05-04	Biosante Pharmaceuticals, Inc.	Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005042581A2 (en)	2003-11-01	2005-05-12	Biovation Ltd.	Modified anti-cd52 antibody
US20060204496A1 (en)	2003-11-28	2006-09-14	Tetsuo Kojima	Agonist antibody against heteroreceptor
ITRM20030601A1 (it) *	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en)	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
KR20080039843A (ko)	2005-05-24	2008-05-07	아베스타 겐그레인 테크놀로지스 피브이티 리미티드	만성 림프구성 백혈병의 치료를 위한 ｃｄ52 에 대한모노클로날 항체의 제조를 위한 재조합 방법
CN102441163A (zh) *	2005-05-27	2012-05-09	比奥根艾迪克Ma公司	结合tweak的抗体
KR20080090484A (ko)	2005-12-30	2008-10-08	메르크 파텐트 게엠베하	ＧＰ130 에 대한, ＩＬ-6Ｒα 와 복합체를 형성한 ＩＬ-6의 결합을 방해하는 항-ＩＬ-6 항체
ES2423481T3 (es)	2006-04-12	2013-09-20	Genzyme Corporation	Métodos de tratamiento de enfermedades autoinmunes
SI2066352T1 (sl)	2006-09-13	2016-05-31	Alcafleu Management Gmbh & Co. Kg	Zdravljenje multiple skleroze (MS) s Campath-1 H
US9498528B2 (en)	2006-09-13	2016-11-22	Genzyme Corporation	Treatment of multiple sclerosis (MS)
US20100135998A1 (en) *	2007-02-28	2010-06-03	Schering Corporation	Combination therapy for treatment of immune disorders
CA2689408A1 (en)	2007-06-22	2008-12-31	Bayer Schering Pharma Aktiengesellschaft	Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
CA2761885A1 (en)	2009-05-13	2010-11-18	Genzyme Corporation	Methods and compositions for treating lupus
EP2429584A4 (en)	2009-05-13	2013-02-20	Genzyme Corp	TREATMENT PROCEDURE AND COMPOSITIONS
BRPI1013085A2 (pt)	2009-05-13	2020-11-03	Genzyme Corporation	imunoglobulinas anti-cd52 humana
SG177653A1 (en) *	2009-07-15	2012-02-28	Aimm Therapeutics Bv	Gram-positive bacteria specific binding compounds
AU2011279073B2 (en) *	2010-07-16	2016-06-09	Adimab, Llc	Antibody libraries

2014
- 2014-03-10 AR ARP140100806A patent/AR095199A1/es unknown
- 2014-03-13 TW TW103108914A patent/TWI644923B/zh not_active IP Right Cessation
- 2014-03-13 MX MX2015012991A patent/MX2015012991A/es unknown
- 2014-03-13 PE PE2015001992A patent/PE20151757A1/es not_active Application Discontinuation
- 2014-03-13 WO PCT/US2014/026159 patent/WO2014151644A2/en active Application Filing
- 2014-03-13 BR BR112015022464A patent/BR112015022464A2/pt not_active Application Discontinuation
- 2014-03-13 TR TR2019/00638T patent/TR201900638T4/tr unknown
- 2014-03-13 SG SG11201506932SA patent/SG11201506932SA/en unknown
- 2014-03-13 CN CN201480028098.XA patent/CN105209495B/zh not_active Expired - Fee Related
- 2014-03-13 PT PT14714135T patent/PT2970467T/pt unknown
- 2014-03-13 ES ES14714135T patent/ES2710976T3/es active Active
- 2014-03-13 CA CA2906539A patent/CA2906539A1/en not_active Abandoned
- 2014-03-13 JP JP2016502067A patent/JP6482524B2/ja not_active Expired - Fee Related
- 2014-03-13 KR KR1020157029345A patent/KR20150131286A/ko not_active Application Discontinuation
- 2014-03-13 LT LTEP14714135.2T patent/LT2970467T/lt unknown
- 2014-03-13 AU AU2014233685A patent/AU2014233685B2/en not_active Ceased
- 2014-03-13 DK DK14714135.2T patent/DK2970467T3/en active
- 2014-03-13 PL PL14714135T patent/PL2970467T3/pl unknown
- 2014-03-13 US US14/774,911 patent/US9708407B2/en active Active
- 2014-03-13 MA MA38485A patent/MA38485A1/fr unknown
- 2014-03-13 NZ NZ631473A patent/NZ631473A/en not_active IP Right Cessation
- 2014-03-13 EA EA201591796A patent/EA031730B1/ru not_active IP Right Cessation
- 2014-03-13 SI SI201431047T patent/SI2970467T1/sl unknown
- 2014-03-13 HU HUE14714135A patent/HUE041796T2/hu unknown
- 2014-03-13 EP EP14714135.2A patent/EP2970467B1/en active Active
- 2014-03-14 UY UY0001035440A patent/UY35440A/es not_active Application Discontinuation
2015
- 2015-08-31 DO DO2015000211A patent/DOP2015000211A/es unknown
- 2015-09-02 PH PH12015501932A patent/PH12015501932A1/en unknown
- 2015-09-09 IL IL241410A patent/IL241410A0/en unknown
- 2015-09-09 GT GT201500267A patent/GT201500267A/es unknown
- 2015-09-11 TN TN2015000415A patent/TN2015000415A1/en unknown
- 2015-09-14 CL CL2015002705A patent/CL2015002705A1/es unknown
- 2015-10-13 CR CR20150547A patent/CR20150547A/es unknown
2016
- 2016-07-11 HK HK16108030.7A patent/HK1219963A1/zh not_active IP Right Cessation
2017
- 2017-06-16 US US15/625,361 patent/US20170349665A1/en not_active Abandoned
2018
- 2018-12-07 JP JP2018229547A patent/JP2019069960A/ja active Pending
2019
- 2019-01-15 HR HRP20190085TT patent/HRP20190085T1/hr unknown
- 2019-01-17 CY CY20191100066T patent/CY1121795T1/el unknown

Also Published As

Publication number	Publication date
CR20150547A (es)	2016-01-08
AU2014233685A1 (en)	2015-10-01
PL2970467T4 (pl)	2019-07-31
US9708407B2 (en)	2017-07-18
AU2014233685B2 (en)	2019-02-28
PE20151757A1 (es)	2015-12-03
MX2015012991A (es)	2015-12-15
CY1121795T1 (el)	2020-07-31
EP2970467A2 (en)	2016-01-20
BR112015022464A2 (pt)	2017-10-24
CL2015002705A1 (es)	2016-04-22
DK2970467T3 (en)	2019-02-11
KR20150131286A (ko)	2015-11-24
SG11201506932SA (en)	2015-09-29
WO2014151644A3 (en)	2015-01-15
TR201900638T4 (tr)	2019-03-21
EP2970467B1 (en)	2018-10-17
NZ631473A (en)	2017-09-29
TN2015000415A1 (en)	2017-01-03
TWI644923B (zh)	2018-12-21
DOP2015000211A (es)	2015-11-30
PL2970467T3 (pl)	2019-07-31
MA38485A1 (fr)	2017-06-30
JP2019069960A (ja)	2019-05-09
AR095199A1 (es)	2015-09-30
TW201522373A (zh)	2015-06-16
EA201591796A1 (ru)	2016-01-29
US20160024219A1 (en)	2016-01-28
IL241410A0 (en)	2015-11-30
JP2016518333A (ja)	2016-06-23
HRP20190085T1 (hr)	2019-03-08
HUE041796T2 (hu)	2019-05-28
CA2906539A1 (en)	2014-09-25
JP6482524B2 (ja)	2019-03-13
US20170349665A1 (en)	2017-12-07
WO2014151644A2 (en)	2014-09-25
HK1219963A1 (zh)	2017-04-21
UY35440A (es)	2014-10-31
CN105209495B (zh)	2020-06-26
EA031730B1 (ru)	2019-02-28
SI2970467T1 (sl)	2019-03-29
LT2970467T (lt)	2019-02-11
ES2710976T3 (es)	2019-04-29
PH12015501932A1 (en)	2016-01-04
GT201500267A (es)	2017-12-15
CN105209495A (zh)	2015-12-30

Publication	Publication Date	Title
IL269528A (en)	2019-11-28	Anti- FCRH5 antibodies
GB201322583D0 (en)	2014-02-05	Antibodies
HK1220142A1 (zh)	2017-04-28	抗體
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
HRP20190085T1 (hr)	2019-03-08	Anti-cd52 protutijela
IL245488B (en)	2020-03-31	Anti- ccl17 antibodies
GB201318283D0 (en)	2013-11-27	Antibodies